Introduction
============

According to the Global Initiative for Obstructive Lung Diseases (GOLD), chronic obstructive pulmonary disease (COPD) is associated with an abnormal inflammatory response of the lungs, which is accompanied by a not fully reversible airflow limitation.[@b1-por-1-015] The pronounced chronic inflammatory process is thought to increase the risk for lung cancer due to constant tissue damage and exposure to substances with mutagenic potential such as reactive oxygen species.[@b2-por-1-015],[@b3-por-1-015] For other organ systems, similar associations between chronic inflammation and cancer have been discussed, such as chronic hepatitis and liver cancer.[@b4-por-1-015] Asthma is another major obstructive lung disease with substantial inflammation; although studies on the association between asthma and lung cancer reported conflicting results, pooled estimates did not provide evidence for an association between asthma and an increased cancer risk.[@b5-por-1-015]--[@b7-por-1-015]

Previous studies on the association between COPD and cancer risk mainly focused on lung cancer, suggesting that COPD increases the risk for lung cancer materially.[@b8-por-1-015]--[@b10-por-1-015] COPD patients and lung cancer patients share an important risk factor, which is smoking. Men have been reported to have higher COPD rates than females, which may be attributed to higher smoking rates in males compared with females in the past, but smoking rates as well as COPD rates in females have been reported to rise.[@b11-por-1-015] In addition, studies indicated that female smokers might be more susceptible to developing COPD than male smokers, as women with COPD tended to suffer from a greater reduction in forced expiratory volume in one second (FEV1).[@b12-por-1-015]

In vitro and in vivo studies have explored potential carcinogenic effects of respiratory drugs, but clinical and epidemiological data are scarce. Theophylline and rolipram -- a more selective phosphodiesterase (PDE) inhibitor -- are thought to mediate antiapoptotic effects by inhibition of the anti-apoptotic Bcl2 protein and by induction of the pro-apoptotic Bax protein in cultured H1299 non-small lung carcinoma cells (NSCLC) and in B-cells from chronic lymphocytic leukemia (CLL) patients.[@b13-por-1-015],[@b14-por-1-015] Positive effects were also seen in CLL patients receiving theophylline alone or in combination with chlorambucil.[@b15-por-1-015],[@b16-por-1-015] Systemic corticosteroid use, on the other hand, has been reported to increase the risk for skin cancer, but no such association was seen with inhaled steroids.[@b17-por-1-015] In vivo studies, however, suggested anti-proliferative effects of glucocorticoids potentially inhibiting the growth of lung cancer.[@b18-por-1-015]--[@b20-por-1-015] The authors of a recent study reported a reduced lung cancer risk in US veterans exposed to high doses of inhaled steroids.[@b21-por-1-015] Another study that investigated the role of antiasthmatic drug use and cancer risk in asthma patients did not find an association between use of inhaled bronchodilators and lung cancer risk, and only a slight increase in risk associated with use of oral steroids.[@b22-por-1-015]

In this study we explored the association between COPD and the risk of developing cancer, and we investigated whether the lung cancer risk is associated with use of respiratory drugs among patients with COPD.

Methods
=======

Data source
-----------

We used the UK-based General Practice Research Database (GPRD) to conduct a follow-up study with a nested case-control analysis. The GPRD has been described in detail elsewhere.[@b23-por-1-015] It is a large primary care database established in 1987 that encompasses some five million patients who are enrolled with selected general practitioners (GPs) throughout the UK. The GPs, who contribute data to the GPRD, have been trained to record medical information in a standard manner and to supply it anonymously. The recorded information includes demographics, medical diagnoses, and virtually all drug prescriptions. The patients enrolled in the GPRD are representative of the UK population in respect of age, sex, and geographical distribution.[@b23-por-1-015] The GPRD has been used before for studies of COPD and cancer.[@b22-por-1-015]

The GPRD is managed by the Medicines and Healthcare products Regulatory Agency (MHRA), and the study protocol was approved by the Independent Scientific Advisory Committee for MHRA database research (ISAC). The investigators only had access to anonymized information.

Study population
----------------

We identified in the GPRD all patients with a first-time diagnosis of COPD (based on medical Read or OXMIS codes) between January 1, 1995 and December 31, 2005 at age 40--79 years. We excluded patients with less than 3 years of active recording history prior to the date of the first COPD diagnosis. In addition, we identified at random from the GPRD one comparison subject without COPD for each COPD patient, matched 1:1 on age (same year of birth), sex, general practice, and calendar time (ie, the date of the first COPD diagnosis of the COPD patient). We applied the same exclusion criteria to the comparison group as to the COPD patients.

Follow-up analysis
------------------

We excluded all patients from the COPD and the COPD-free comparison group with a recorded history of cancer (excluding non-melanoma skin cancer), HIV, drug abuse, or alcoholism prior to the COPD diagnosis (or the corresponding date in the COPD-free group). We then followed all remaining patients from the start of follow-up (ie, the COPD diagnosis date or the corresponding date in the comparison group) and assessed the person-time for each patient until he or she developed an incident diagnosis of cancer, left the database, died, or reached the end of the study (December 31, 2005), whatever came first. We estimated incidence rates with 95% confidence intervals (CI) separately for COPD patients and COPD-free patients and stratified by age and gender.

Nested case-control analysis
----------------------------

We conducted a nested case-control analysis to further analyze the impact of COPD, respiratory drugs, and various potential confounders on the risk of developing cancer. For this purpose we identified for each case with an incident cancer diagnosis four control patients selected at random from the study population (ie, patients with or without COPD who did not develop cancer during follow-up). These controls were matched to cases on age, sex, practice, and index date (ie, the date when the case had the incident cancer diagnosis). We compared the prevalence of COPD in patients with cancer and controls using conditional logistic regression analyses.

We provided the risk estimates stratified for different cancer sites and adjusted for patient characteristics such as body mass index (BMI \<18.5, 18.5--25, 25--29.9, 30--60 kg/m^2^, or unknown), smoking history (no, current, past, unknown), as well as for various cancer type specific confounders (breast cancer: contraceptive use, hormone replacement therapy use, benign neoplasms, non-melanoma skin cancer, and NSAID use; lymphoma: benign neoplasms, use of carcinogenic drugs; gastro-esophageal cancer: gastro-esophageal reflux disease, benign neoplasms, non-melanoma skin cancer; colorectal cancer: NSAID use, constipation, benign neoplasms, non-melanoma skin cancer; female reproductive system cancer: contraceptive use, hormone replacement therapy use, benign neoplasm, non-melanoma skin cancer, NSAID use; urinary system cancers: hypertension, benign neoplasms, use of diuretics, use of carcinogenic drugs, urinary dysfunction).

Drug exposure
-------------

To analyze the association between respiratory medication and lung cancer risk we stratified patients into 'non-users', 'current users', or 'past users'. Current users were patients who received their last prescription within 180 days prior to the lung cancer diagnosis, and past users were all the patients who had prescriptions for the drugs of interest recorded \>180 days prior to the lung cancer diagnosis. We further subdivided 'current use' into 'current short-term use' of less then a year (ie, patients have had their first drug prescription within a year prior to the diagnosis), of 1--3 years, or of \>3 years. We also divided current and past users into 'regular' or 'intermittent' user; in order to be a 'regular user', patients had to have at least one prescription recorded every 100 days, and if a patient was a current user with less than one prescription every 100 days, the patient was an 'intermittent user'.

Statistical analyses were performed with the statistical software SAS (release 9.1, SAS Institute, Inc, Cary, NC, USA).

Results
=======

The study population consisted of 35,772 COPD patients and the same number of matched COPD-free patients, 51.3% of them being male.

Within the study population, we identified a total of 4506 cancer cases during follow-up, 2585 among the COPD patients and 1921 among the COPD-free patients. Sixty-one percent of all cancer cases were men ([Table 1](#t1-por-1-015){ref-type="table"}). The incidence rates (IRs) were 27.8/1000 person-years (py) among COPD-patients, and 16.8/1000 py among COPD-free patients ([Table 2](#t2-por-1-015){ref-type="table"}). IRs were higher among men than among women, but the incidence rate ratio (IRR) associated with COPD was slightly higher in females than in males. The cancer IR increased with age.

In the nested case-control analysis we explored the association between a history of COPD and the risk of developing various types of cancer, stratified by gender ([Tables 3](#t3-por-1-015){ref-type="table"} and [4](#t4-por-1-015){ref-type="table"}). The relative risk was highest for developing lung cancer, and it was particularly high in women; OR 5.26 (95% CI 3.64--7.61), compared with men: OR 2.10 (95% CI 1.70--2.60) (likelihood ratio test *P* \< 0.001). The crude risk of developing urinary/kidney cancer (in both men and women) was also increased, but after adjustment for potential confounders the ORs were no longer statistically significantly increased. The relative risk of developing one of the other cancer types was not or only marginally altered in association with a previous COPD diagnosis.

To further analyze the association between COPD and lung cancer we did an analysis stratified by smoking status. The presence of COPD increased the risk of being diagnosed with lung cancer in non-smokers (OR 4.21, 95% CI 2.65--6.69) ([Table 5](#t5-por-1-015){ref-type="table"}).

In a second sensitivity analysis on the association between COPD and lung cancer we assessed respiratory drug use in detail among COPD patients ([Table 6](#t6-por-1-015){ref-type="table"}). The exposure prevalence to these drugs was high; short-acting beta agonists were used by 70%--80%, short-acting anticholinergic drugs by 30%--40%, and inhaled corticosteroids by more than 50% of COPD patients. For most drugs the proportion of lung cancer cases and controls using respiratory drugs on a longer-term basis was similar, yielding relative risk estimates around one. There was a tendency towards increased relative cancer risks associated with short-term current use of most respiratory drugs, which can be explained by a worsening of COPD symptoms prior to the lung cancer diagnosis. This effect was particularly strong for short-term current oxygen users with an OR of 5.06 (95% CI 2.87--8.90), and there was also a suggestion of an increased lung cancer risk associated with current long-term theophylline use (adjusted OR 2.37, 95% CI 1.05--5.35).

Discussion
==========

In this large population-based study, the overall cancer risk was increased in COPD patients as compared with COPD-free patients. This increased risk was mainly driven by the increased lung cancer risk. There was also a suggestion of an increased cancer risk for cancers of the urinary and gastrointestinal tract, but after adjusting for smoking and other covariates the risk estimates no longer reached statistical significance. Smoking is the most important risk factor for both COPD and lung cancer, and it is likely that most of the observed lung cancer risk is due to smoking. However, stratification by smoking status showed that COPD increased the risk in non-smokers when comparing non-smoking COPD patients with non-smoking patients without COPD, which indicates an independent contribution of COPD on the lung cancer risk. This proposition is consistent with findings from previous studies reporting risk estimates ranging from 1.5 to 2.7 for various levels of COPD severity.[@b8-por-1-015],[@b9-por-1-015],[@b24-por-1-015] Based on our findings from an observational study we cannot tell whether the substantially increased OR of 4.21 (95% CI 2.65--6.69) for lung cancer among non-smoking COPD patients points to a smoking-independent association between COPD and lung cancer risk, or whether it is the result of residual confounding or smoking misclassification; we cannot rule out that the result is driven to some degree by misclassification of tobacco exposure, ie, a patient being recorded as a nonsmoker despite a previous history of smoking. Furthermore, a COPD diagnosis may be made by mistake because someone is presenting with lung cancer symptoms.

Our findings were also similar to the ones in a previous analysis on lung diseases and cancer risk on the same database that covered the period from 1994 to 2001 and encompassed only some 9000 subjects with COPD; our study was done between 1995 and 2005 and involved some 35,000 COPD patients.[@b22-por-1-015] Furthermore, we stratified the results of the nested case-control analysis by gender, which was not done in the previous study.[@b22-por-1-015]

Overall, the distribution of various cancer types in the current study population reflects what is known from cancer statistics: in men, lung cancer and cancer of the reproductive system (mainly prostate cancer) are the most frequent cancer types, followed by colorectal cancer; in women, lung, breast, and colorectal cancer are the most common malignancies. We observed higher relative lung cancer risk estimates associated with a history of COPD for women than for men; whether this points towards a greater susceptibility for women, or whether it is due to other factors and needs to be further explored, is unknown and controversially discussed. Women outnumber men in the population of non-smoking COPD patients.

We did not find much evidence for an altered lung cancer risk in association with long-term use of various respiratory drugs. The increased relative risk seen for short-term current drug users is most likely due to the fact that respiratory function decreased shortly prior to the lung cancer diagnosis, which led to the initiation of a new drug treatment. This finding indicates that COPD patients with an acute deterioration of their lung function need careful evaluation because one of several reasons for the worsening clinical situation might be the first manifestation of lung cancer. There was a suggestion of an increased risk of developing lung cancer associated with long-term theophylline use, but this finding was based on a relatively small number of exposed cases and controls and may be a chance finding; this cannot be ruled out, particularly if a substantial number of exposure categories are tested in the model. It may also reflect a more advanced and severe stage of COPD and thereby be the result of confounding by indication.

Parimon et al reported that high doses of inhaled corticosteroids (\>1200 mcg/d) reduced the risk of a lung cancer diagnosis significantly when compared with non-users.[@b21-por-1-015] Kiri et al also reported a reduced lung cancer risk in patients using inhaled corticosteroids alone or in combination with long-acting beta agonists when compared with patients using short-acting beta agonists.[@b25-por-1-015] In our study population, we did not see a significant association between corticosteroid use and the risk of lung cancer. In women with a cancer diagnosis, there was a tendency towards a decreased exposure history to inhaled corticosteroids as compared with cancer-free controls, but the adjusted analysis did not yield a statistically reduced risk estimate (data not shown). There was no such effect seen in men. In a study involving asthma patients, use of oral corticosteroids was associated with an increased cancer risk.[@b22-por-1-015]

An important limitation of this study is the limited follow-up time between the first COPD diagnosis and the incident cancer diagnosis. Both COPD and cancer are chronic diseases that develop and are present for some time before first symptoms become clinically manifest. Thus, we may have missed a certain proportion of patients with mild COPD who had not yet been diagnosed by the GP. Further, the proportion of patients with severe COPD may be small due to limited follow-up. Thus, the current study population may reflect a patient population with a relatively high proportion of moderate COPD. In addition, it would have been desirable to have more information on certain potential risk factors (eg, human papilloma virus infections) or protective factors (eg, former use of oral contraceptives (OCs)) for various gynecological cancers. We assessed OC use prior to the index date for women in the nested case-control analysis and adjusted the analyses for this parameter, but for elderly women the likelihood of having previous OC use recorded on computer was low. By matching cancer cases and controls in practice, we made an attempt to take socioeconomic status into account to some degree, as social deprivation shows a geographical pattern and therefore people from the same neighborhood are more likely to see the same GP. We adjusted all our analyses for smoking status; however, we cannot exclude residual confounding by environmental tobacco exposure or smoking intensity.

A strength of this study is that the GPRD is a well-validated data source with a high validity of recorded drug exposure. In addition, all drug use was recorded prior to these analyses and in the absence of any study hypothesis. Further, we classified drug use in all patients (ie, cases or controls, or patients with or without COPD) in the same way so that any exposure misclassification should be non-differentially distributed across users of various COPD medications.

In summary, this observational study provides further evidence that COPD is only marginally or not at all associated with most cancers except lung cancer. The risk of developing lung cancer is substantially increased for COPD patients, which can in part be explained by smoking as a major common underlying risk factor, but an independent association between chronic lung inflammation due to COPD and an increased cancer risk beyond the effect of smoking is also possible. In our study population, the risk of developing lung cancer in association with COPD was higher in women than in men.

This study was funded by an unconditional grant by Nycomed GmbH.
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###### 

Characteristics of cancer cases and controls

                    Cases   Controls          
  ----------------- ------- ---------- ------ ------
  Age                                         
   40--49           26      19         89     94
   50--59           217     139        706    788
   60--69           743     496        2357   2612
   70--79           1329    992        4343   4775
   80+              270     275        727    899
  Men               1526    1207       5008   5521
  Smoking status                              
   Non-smoker       432     896        1915   4673
   Current smoker   1049    355        2713   1350
   Ex-smoker        926     490        3016   2144
   Unknown          178     180        578    1001
  BMI                                         
   15--18.4         126     28         326    87
   18.5--24.9       930     593        2750   2791
   25.0--29.9       699     696        2399   3161
   30.0--60.0       380     282        1332   1470
   Unknown          450     322        1414   1660
  Asthma            1266    242        4204   861

###### 

Incidence rate and rate ratio: all cancers by age, gender, and COPD status

                   No. of cases   Person- years (py)   IR per 1000 py   95% CI       IRR          95% CI
  --------- ------ -------------- -------------------- ---------------- ------------ ------------ ------------
  No COPD          1921           114441.4             16.8             16.1--17.5   1.00         ref
  COPD             2585           92923.9              27.8             26.8--28.9   1.64         1.55--1.74
  Sex                                                                                             
  Male      NC     1207           56919.3              21.2             20.1--22.4   1.00         ref
  C         1526   45642.3        33.4                 31.8--35.1       1.56         1.45--1.68   
  Female    NC     714            57522.1              12.4             11.5--13.4   1.00         ref
  C         1059   47281.7        22.4                 21.1--23.8       1.79         1.63--1.96   
  Age                                                                                             
  \<50y     NC     19             5133.0               3.7              2.4--5.8     1.00         ref
  C         26     4672.2         5.6                  3.8--8.1         1.50         0.84--2.69   
  50--59y   NC     139            19374.0              7.2              6.1--8.5     1.00         ref
  C         217    17462.4        12.4                 10.9--14.2       1.72         1.40--2.12   
  60--69y   NC     496            36029.7              13.8             12.6--15.0   1.00         ref
  C         743    30570.8        24.3                 22.6--26.1       1.75         1.56--1.95   
  70--79y   NC     992            44520.8              22.3             21.0--23.7   1.00         ref
  C         1329   34239.1        38.8                 36.8--40.9       1.71         1.58--1.82   
  ≥ 80y     NC     275            9383.9               29.3             26.1--32.9   1.00         ref
  C         270    5979.5         45.2                 40.2--50.7       1.52         1.28--1.80   

**Abbreviations:** C, COPD; CI, confidence interval; IR, incidence rate; IRR, incidence rate ratio; NC, no COPD; py, person-years; ref, reference category; y, years.

###### 

Cancer risk in women

                              Cases (N = 1007)   Controls (N = 4028)   OR (95% CI)         Adjusted OR (95% CI)
  --------------------------- ------------------ --------------------- ------------------- ----------------------
  Gastro-esophageal cancers                                                                
   No COPD                    19                 93                    1.0                 1.0
   COPD                       26                 87                    1.44 (0.75--2.76)   0.92 (0.43--1.98)
  Intestinal cancers                                                                       
   No COPD                    51                 233                   1.0                 1.0
   COPD                       63                 223                   1.28 (0.85--1.91)   1.14 (0.73--1.77)
  Lymphoma                                                                                 
   No COPD                    24                 89                    1.0                 1.0
   COPD                       18                 79                    0.86 (0.45--1.65)   0.86 (0.45--1.65)
  Breast cancer                                                                            
   No COPD                    170                687                   1.0                 1.0
   COPD                       167                661                   1.02 (0.81--1.28)   1.06 (0.82--1.38)
  Female genital cancers                                                                   
   No COPD                    53                 184                   1.0                 1.0
   COPD                       35                 168                   0.74 (0.47--1.17)   0.82 (0.48--1.37)
  Urinary/Kidney cancers                                                                   
   No COPD                    22                 125                   1.0                 1.0
   COPD                       38                 115                   1.86 (1.04--3.33)   1.88 (0.83--4.27)
  Lung cancer                                                                              
   No COPD                    41                 733                   1.0                 1.0
   COPD                       280                551                   8.35 (5.90--11.8)   5.26 (3.64--7.61)

**Notes:** OR adjusted for BMI, smoking, and various cancer type specific confounders. Breast cancer: contraceptive use, hormone replacement therapy use, benign neoplasms, non-melanoma skin cancer, and NSAID use; lymphoma: benign neoplasms, use of carcinogenic drugs; gastro-esophageal cancer: gastro-esophageal reflux disease, benign neoplasms, non-melanoma skin cancer; colorectal cancer: NSAID use, constipation, benign neoplasms, non-melanoma skin cancer; female reproductive system cancer: contraceptive use, hormone replacement therapy use, benign neoplasm, non-melanoma skin cancer, NSAID use; urinary system cancers: hypertension, benign neoplasms, use of diuretics, use of carcinogenic drugs, urinary dysfunction.

**Abbreviations:** CI, confidence interval; OR, odds ratio.

###### 

Cancer risk in men

                              Cases (N = 1643)   Controls (N = 6572)   OR (95% CI)         Adjusted OR (95% CI)
  --------------------------- ------------------ --------------------- ------------------- ----------------------
  Gastro-esophageal cancers                                                                
   No COPD                    63                 264                   1.0                 1.0
   COPD                       58                 220                   1.09 (0.75--1.60)   1.03 (0.69--1.54)
  Intestinal cancers                                                                       
   No COPD                    90                 390                   1.0                 1.0
   COPD                       93                 342                   1.17 (0.85--1.60)   1.24 (0.88--1.74)
  Lymphoma                                                                                 
   No COPD                    34                 137                   1.0                 1.0
   COPD                       38                 151                   1.01 (0.61--1.68)   1.01 (0.61--1.68)
  Male genital cancers                                                                     
   No COPD                    270                1066                  1.0                 1.0
   COPD                       231                938                   0.97 (0.81--1.18)   1.01 (0.83--1.24)
  Urinary/Kidney cancers                                                                   
   No COPD                    95                 444                   1.0                 1.0
   COPD                       121                420                   1.34 (0.99--1.80)   1.08 (0.75--1.57)
  Lung cancer                                                                              
   No COPD                    146                1172                  1.0                 1.0
   COPD                       404                1028                  2.93 (2.40--3.59)   2.10 (1.70--2.60)

**Notes:** OR adjusted for BMI, smoking, and various cancer type specific confounders. Lymphoma: benign neoplasms, use of carcinogenic drugs; gastro-esophageal cancer: gastro-esophageal reflux disease, benign neoplasms, non-melanoma skin cancer; colorectal cancer: NSAID use, constipation, benign neoplasms, non-melanoma skin cancer; urinary system cancers: hypertension, benign neoplasms, use of diuretics, use of carcinogenic drugs, urinary dysfunction.

**Abbreviations:** CI, confidence interval; OR, odds ratio.

###### 

Lung cancer risk stratified by smoking status

                    Cases   Controls   Crude OR (95% CI)      Adjusted OR (95% CI)
  ----------------- ------- ---------- ---------------------- ----------------------
  No COPD                                                     
   Non-smoker       32      959        1.00 (ref)             1.00 (ref)
   Current smoker   85      281        9.23 (6.00--14.21)     9.04 (5.87--13.94)
   Ex-smoker        60      446        3.99 (2.55--6.24)      4.13 (2.63--6.46)
  COPD                                                        
   Non-smoker       52      339        4.26 (2.69--6.76)      4.21 (2.65--6.69)
   Current smoker   337     545        17.19 (11.77--25.09)   16.25 (11.10--23.78)
   Ex-smoker        248     581        11.48 (7.81--16.86)    11.62 (7.90--17.09)

**Note:** OR adjusted for BMI and all variables in the table.

**Abbreviations:** CI, confidence interval; OR odds ratio; ref, reference category.

###### 

Lung cancer stratified risk by medication use

                                      Cases (%) (N = 684)   Controls (%) (N = 1579)   Adjusted OR   95% CI
  ----------------------------------- --------------------- ------------------------- ------------- -------------
  **Short-acting beta agonists**                                                                    
  No use                              161 (23.5)            379 (24.0)                ref           ref
  Current \<1y                        87 (12.7)             133 (8.4)                 1.37          0.94--1.99
  Current 1--3y                       55 (8.0)              112 (7.1)                 1.15          0.74--1.77
  Current \>3y                        149 (21.8)            365 (23.1)                1.00          0.69--1.43
  Current few                         120 (17.5)            246 (15.6)                1.33          0.95--1.87
  Past regularly                      68 (9.9)              203 (12.9)                0.90          0.63--1.30
  Past few                            44 (6.4)              141 (8.9)                 0.87          0.56--1.34
  **Long-acting beta agonists**                                                                     
  No use                              549 (80.3)            1197 (75.8)               ref           ref
  Current \<1y                        33 (4.8)              88 (5.6)                  0.64          0.41--1.02
  Current 1--3y                       24 (3.5)              63 (4.0)                  0.80          0.46--1.40
  Current \>3y                        22 (3.2)              61 (3.9)                  0.92          0.52--1.65
  Current few                         10 (1.5)              21 (1.3)                  1.28          0.55--3.00
  Past regularly                      39 (5.7)              125 (7.9)                 0.69          0.45--1.08
  Past few                            7 (1.0)               24 (1.5)                  0.75          0.28--2.01
  **Short-acting anticholinergics**                                                                 
  No use                              450 (65.8)            1084 (68.7)               ref           ref
  Current \<1y                        76 (11.1)             109 (6.9)                 1.33          0.93--1.90
  Current 1--3y                       23 (3.4)              64 (4.1)                  0.81          0.46--1.41
  Current \>3y                        41 (6.0)              87 (5.5)                  1.38          0.87--2.20
  Current few                         18 (2.6)              25 (1.6)                  2.00          0.99--4.04
  Past regularly                      61 (8.9)              176 (11.2)                0.86          0.60--1.23
  Past few                            15 (2.2)              34 (2.2)                  1.35          0.68--2.68
  **Tiotropium**                                                                                    
  No use                              633 (92.5)            1512 (95.8)               ref           ref
  Current \<1y                        36 (5.3)              46 (2.9)                  1.70          0.98--2.95
  Current 1--3y                       7 (1.0)               15 (1.0)                  1.24          0.44--3.49
  Current \>3y                        --                    --                        --            --
  Current few                         --                    --                        --            --
  Past regularly                      8 (1.2)               6 (0.4)                   3.31          1.05--10.45
  Past few                            --                    --                        --            --
  **Inhaled corticosteroids**                                                                       
  No use                              309 (45.2)            667 (42.2)                ref           ref
  Current \<1y                        78 (11.4)             121 (7.7)                 1.23          0.85--1.78
  Current 1--3y                       46 (6.7)              11 (7.0)                  0.80          0.52--1.25
  Current \>3y                        121 (17.7)            341 (21.6)                0.83          0.59--1.17
  Current few                         67 (9.8)              158 (10.0)                0.56          0.59--1.25
  Past regularly                      45 (6.6)              114 (7.2)                 0.91          0.59--1.39
  Past few                            18 (2.6)              67 (4.2)                  0.68          0.37--1.26
  **Theophylline**                                                                                  
  No use                              611 (89.3)            1434 (90.8)               ref           ref
  Current \<1y                        7 (1.0)               16 (1.0)                  1.29          0.47--3.50
  Current 1--3y                       4 (0.6)               11 (0.7)                  0.85          0.23--3.12
  Current \>3y                        13 (1.9)              17 (1.1)                  2.37          1.05--5.35
  Current few                         2 (0.3)               11 (0.7)                  0.57          0.12--2.77
  Past regularly                      34 (5.0)              63 (4.0)                  1.38          0.83--2.29
  Past few                            13 (1.9)              27 (1.7)                  1.47          0.65--3.33
  **Other xanthines**                                                                               
  No use                              628 (91.8)            1443 (91.4)               ref           ref
  Current \<1y                        13 (1.9)              9 (0.6)                   5.05          1.86--13.72
  Current 1--3y                       6 (0.9)               8 (0.5)                   1.52          0.48--4.82
  Current \>3y                        11 (4.6)              29 (1.8)                  0.82          0.36--1.86
  Current few                         2 (0.3)               3 (0.2)                   1.51          0.19--12.18
  Past regularly                      19 (2.8)              75 (4.8)                  0.67          0.38--1.19
  Past few                            5 (0.7)               12 (0.8)                  1.29          0.40--4.13
  **Oxygen**                                                                                        
  No use                              623 (91.1)            1507 (95.4)               ref           ref
  Current \<1y                        44 (6.4)              24 (1.5)                  5.06          2.87--8.90
  Current 1--3y                       5 (0.7)               9 (0.6)                   1.16          0.33--4.09
  Current \>3y                        4 (0.6)               7 (0.4)                   1.26          0.31--5.16
  Current few                         1 (0.2)               4 (0.3)                   0.59          0.06--5.87
  Past regularly                      6 (0.9)               25 (1.6)                  0.56          0.21--1.49
  Past few                            1 (0.2)               3 (0.2)                   1.14          0.10--12.49

**Notes:** OR adjusted for smoking status, COPD status, BMI, and all the variables in the table.

**Abbreviations:** CI, confidence interval; OR, odds ratio; ref, reference category.
